Vertex reported that the drug it acquired in a multibillion‑dollar deal met its primary endpoint in a Phase 3 study for IgA nephropathy, cutting a key disease marker by roughly 50%. The company said the outcome mirrors competing data for Otsuka’s Voyxact and outperformed other entrants numerically, reinforcing Vertex’s assessment of best‑in‑class potential. Vertex acquired the asset as part of a $4.9 billion transaction and now positions the program as a major growth driver, with analysts projecting eventual peak sales in the multi‑billion‑dollar range. The readout narrows an active race in kidney disease therapeutics and will shape regulatory submissions and payer expectations for a disease that affects hundreds of thousands in the U.S. and Europe.